Evolutionary biology of high-risk multiple myeloma
The outcomes for the majority of patients with myeloma have improved over recent decades,
driven by treatment advances. However, there is a subset of patients considered to have …
driven by treatment advances. However, there is a subset of patients considered to have …
The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee
Since the publication of the Revised European-American Classification of Lymphoid
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …
Plasma cell neoplasms and related entities—evolution in diagnosis and classification
F Fend, A Dogan, JR Cook - Virchows Archiv, 2023 - Springer
Plasma cell neoplasms including multiple myeloma (MM) and related terminally
differentiated B-cell neoplasms are characterized by secretion of monoclonal …
differentiated B-cell neoplasms are characterized by secretion of monoclonal …
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma
NC Munshi, H Avet-Loiseau, KC Anderson… - Blood …, 2020 - ashpublications.org
The prognostic value of minimal residual disease (MRD) for progression-free survival (PFS)
and overall survival (OS) was evaluated in a large cohort of patients with multiple myeloma …
and overall survival (OS) was evaluated in a large cohort of patients with multiple myeloma …
Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
The iliac crest is the sampling site for minimal residual disease (MRD) monitoring in multiple
myeloma (MM). However, the disease distribution is often heterogeneous, and imaging can …
myeloma (MM). However, the disease distribution is often heterogeneous, and imaging can …
Epidemiology, genetics and treatment of multiple myeloma and precursor diseases
K Hemminki, A Försti, R Houlston… - International journal of …, 2021 - Wiley Online Library
Multiple myeloma (MM) is a hematological malignancy caused by the clonal expansion of
plasma cells. The incidence of MM worldwide is increasing with greater than 140 000 …
plasma cells. The incidence of MM worldwide is increasing with greater than 140 000 …
The impact of tumor heterogeneity on diagnostics and novel therapeutic strategies in multiple myeloma
Myeloma is characterized by extensive inter-patient genomic heterogeneity due to multiple
different initiating events. A recent multi-region sequencing study demonstrated spatial …
different initiating events. A recent multi-region sequencing study demonstrated spatial …
Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
R Fonseca, M Arribas, JE Wiedmeier-Nutor… - Blood cancer …, 2023 - nature.com
Minimal residual disease (MRD) assays allow response assessment in patients with multiple
myeloma (MM), and negativity is associated with improved survival outcomes. The role of …
myeloma (MM), and negativity is associated with improved survival outcomes. The role of …
Future of CAR T cells in multiple myeloma
K Wudhikarn, S Mailankody… - Hematology 2014, the …, 2020 - ashpublications.org
Despite the significant improvement in survival outcomes of multiple myeloma (MM) over the
past decade, it remains an incurable disease. Patients with triple-class refractory MM have …
past decade, it remains an incurable disease. Patients with triple-class refractory MM have …
Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
Multiple myeloma (MM) patients frequently attain a bone marrow (BM) minimal residual
disease (MRD) negativity status in response to treatment. We identified 568 patients who …
disease (MRD) negativity status in response to treatment. We identified 568 patients who …